DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist with the molecular structure p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2. It is effectively used in tracing tumors in vivo through isotopic labeling, examples being 177Lu-DOTA-LM3 TFA and 68Ga-DOTA-LM3 TFA. The 68Ga-labeled compound demonstrates favorable biodistribution, high tumor uptake, good tumor retention, and minimal safety concerns. Meanwhile, the 177Lu-labeled variant is utilized in research targeting DOTATOC-negative liver metastases such as pancreatic NET and extensive tumor thrombosis [1] [2].

177Lu-DOTA-LM3 TFA 被证明是耐受的，主要在全身、肾、脾及转移病灶中分布，从而使这些器官和肿瘤组织的平均吸收剂量增加[2]。